Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 9, 2006

View Archived Issues

Millennium profiles recent highlights

Antiangiogenic effects of CTCE-9908 could explain its antimetastatic properties

Gilead Sciences: Q4 review

Update on H5N1 vaccine development projects

IND cleared for phase I study of Tramadol ER

BioSante awarded subcontract for recombinant Factor IX formulation work

New sugar-cholestanol with anticancer activity

Phase I/II study shows efficacy of cell therapy for nasopharyngeal carcinoma

Heparan sulfate mimetics tested against dengue virus and flaviviral encephalitis

Therapeutic potential of anthrax lethal toxin in Kaposi's sarcoma

Ono profiles progress of recent months

APEX-AMI pexelizumab trial set to conclude

TRO-19622 completes phase I trials

Solbec prepares for phase II trials of Coramsine

Akzo Nobel to create two independent companies

PBT-2 completes phase I program

European Commission approval for Novartis' acquisition of Chiron

Fortovase discontinued, Invirase preferred option

MC4 antagonist/serotonin transport inhibitor for stress-related anxiety and depression

New Abilify options now available

New treatments for hepatitis C described in recent Boehringer Ingelheim patent

Novel agents imparted for inflammatory disorders

Potent targeting of c-Fos enhances the antiosteogenic activity of new vitamin D analogues

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...